FranceResearch and clinical trials
TRAPS in France's rare disease registry: some registered patients have no gene change
In France, patients with TRAPS in the national rare disease registry were re-examined.
Blood and immune system diseases
An inherited inflammatory disease with long-lasting attacks of fever. During attacks there is muscle pain, abdominal pain and a rash.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Blood and immune system diseases” group.
A change in the TNFRSF1A gene causes a protein called TNF receptor 1 to fold incorrectly. This protein builds up inside the cell and constantly stimulates inflammation. As a result, attacks of fever and inflammation happen without any germs. Attacks usually last 1 to 3 weeks.
The first attack usually happens in childhood. Symptoms may include:
The doctor suspects TRAPS based on the symptoms and family history. During attacks, inflammation markers rise in the blood. The diagnosis is confirmed with a genetic test of the TNFRSF1A gene. The urine is also checked for protein.
Anti-inflammatory medicines and cortisone can be used to ease attacks. Biological medicines that block a substance called IL-1, which starts inflammation, can clearly reduce attacks. There is an approved biological treatment for this disease. People on treatment need regular blood and urine tests. The doctor who follows the disease decides which treatment is suitable.
Inheritance is dominant. For each child of an affected parent, the chance is 1 in 2. Not everyone who carries the gene may become ill. Sometimes the gene change is new. Genetic counselling is recommended for family members with similar complaints.
Source: MedlinePlus Genetics: Tumor necrosis factor receptor-associated periodic syndrome · NORD: Tumor Necrosis Factor Receptor-Associated Periodic Syndrome · PRINTO/PReS: TNF Reseptörüyle İlişkili Periyodik Sendrom (TRAPS)
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
For all rare diseases: Nadir Hastalıklar Federasyonu
Links checked on October 8, 2026.
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
FranceResearch and clinical trials
In France, patients with TRAPS in the national rare disease registry were re-examined.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.
See all studies on ClinicalTrials.gov · Joining clinical trials
GlobalHealth policy
The International Pediatric Nephrology Association published its recommendations for diagnosing and treating atypical HUS in children.
GlobalResearch and clinical trials
Researchers re-examined the data from a large drug study.
TürkiyeResearch and clinical trials
A face-to-face survey was conducted with 104 PNH patients at 18 centers in Türkiye.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:32960 · ICD-11 4A60.2
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.